Kamada Ltd. - Ordinary Shares (KMDA)
6.8500
+0.0700 (1.03%)
NASDAQ · Last Trade: Jun 8th, 1:13 AM EDT
Detailed Quote
Previous Close | 6.780 |
---|---|
Open | 6.780 |
Bid | 6.830 |
Ask | 6.850 |
Day's Range | 6.750 - 6.896 |
52 Week Range | 4.740 - 9.155 |
Volume | 74,918 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | 0.2000 (2.92%) |
1 Month Average Volume | 81,513 |
Chart
About Kamada Ltd. - Ordinary Shares (KMDA)
Kamada Ltd is a biopharmaceutical company that specializes in the development and commercialization of innovative therapeutics for rare and serious diseases. The company focuses on producing protein-based drugs, particularly in the fields of immunology and respiratory medicine, utilizing its proprietary technology platforms. By developing therapies that address unmet medical needs, Kamada aims to improve the quality of life for patients while advancing healthcare solutions in specialized treatment areas. The company actively engages in partnerships and collaborations to enhance its research and development efforts, striving to bring new and effective treatments to market. Read More
News & Press Releases

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · June 6, 2025
DETROIT, MICHIGAN - June 6, 2025 ( NEWMEDIAWIRE ) - Cytomegalovirus (CMV) is a common virus that most adults are exposed to at some point in their lives, and over half of American adults have been infected by age 40 . A healthy immune system can keep the virus at bay, and it’s usually harmless. But for organ transplant recipients, contracting CMV disease can be dangerous and even deadly in some cases. About 20% to 60% of people who have a solid organ transplant develop a symptomatic CMV infection. It's one of the most common complications for solid organ transplant recipients. While effective strategies that often use antiviral medicines to prevent or treat CMV exist, none offer a completely foolproof solution, nor is there any vaccine available to prevent it in advance.
Via TheNewswire.com · June 6, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · April 22, 2025
By Meg Flippin Benzinga
Via TheNewswire.com · April 22, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · April 16, 2025
DETROIT, MICHIGAN - April 16, 2025 ( NEWMEDIAWIRE ) - Amir London, CEO of Kamada Pharmaceuticals (NASDAQ: KMDA), was recently a guest on Benzinga’s All-Access.
Via TheNewswire.com · April 16, 2025
NEW YORK CITY, NY / ACCESS Newswire / March 18, 2025 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day March Small-Cap Conference taking place Wednesday and Thursday, March 19-20, 2025. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
Via ACCESS Newswire · March 18, 2025
Via Benzinga · March 17, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · March 14, 2025
By JE Insights, Benzinga
Via TheNewswire.com · March 14, 2025
By JE Insights, Benzinga
Via TheNewswire.com · February 28, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · February 28, 2025

KMDA stock results show that Kamada beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 14, 2024

Pre-market stock movers are a hot topic on Wednesday and we have all of the biggest stories traders need to know about this morning!
Via InvestorPlace · August 14, 2024

Healthcare innovations are big business. That said, biotech stocks under $10 may offer a higher ceiling thanks to their low price.
Via InvestorPlace · July 29, 2024

KMDA stock results show that Kamada missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 8, 2024

KMDA stock results show that Kamada beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Via InvestorPlace · March 6, 2024

Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million.
Via Benzinga · March 6, 2024

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
Via Benzinga · November 13, 2023